Globally, shigella is reported to be the third largest cause of diarrheal mortality in the under-fives. We take a look at some of the vaccines that have made it to clinical development and some of the challenges still facing this diarrheal disease.
Browsing: Clinical > Vaccines
Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.
In this interview we take a look at cholera outbreak situations and the strategies required to tackle them as we talk to Martin Mengel following his presentation at ECCMID.
A recent study has demonstrated a significant decrease in cases of human papilloma virus infection in England since the introduction of a bivalent vaccine in 2008.
Through a process of elimination, researchers have identified membrane surface proteins on T. pallaidum, which can be targeted by immune antibodies.
At ASM Microbe GeoVax have spoken on the development of single-dose vaccines for emerging diseases using their MVA ‘Plug and Play’ platform technology.
In our latest interview we ask Seth Berkley, who has been CEO of Gavi since 2011, about new vaccines, the importance of collaboration and the challenges facing access to vaccinations.
In this interview Sally, a Senior Research Fellow at Imperial College London’s Faculty of Medicine (London, UK), speaks about her work on issues relating to the vaccination and screening of migrants, in addition to discussing some of the wider issues facing migrant’s access to healthcare in Europe.
Rabies elimination is achievable and cost-effective, but decades of research have failed to translate into multi-national efforts in the worst-affected areas. So why is the ancient rabies virus still terrorizing the lives of so many people across the globe?